Literature DB >> 12206766

Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.

Resi B Gerstner1, Paul Carter, Henry B Lowman.   

Abstract

We have examined the plasticity of the antigen-combining site of a high-affinity antibody. In phage-displayed Fab libraries, selected CDR positions and one FR position of the humanized anti-Her2 antibody hu4D5 were substituted with all 20 amino acids. Antigen-binding selections were used to enrich for high-affinity variants, and a large number of sequences were obtained prior to convergence of the selected pool to a small set of clones. As expected, sequence variability of the antigen-binding site is overall diminished compared to known IgG sequences; however, certain positions retain much higher variability than others. The sequence variability map of the hu4D5 binding site is compared with a map derived from previous alanine-scanning of the antibody. Affinities of soluble Fab fragments for antigen confirm that multiple variants were selected with high affinity for antigen, including one variant with a single point mutation that was about threefold improved in affinity compared to the parental hu4D5. Interestingly, this mutation is one of the most radical in terms of changing side-chain chemistry (Trp for Asp) and occurs at the most plastic site as calculated by the Wu-Kabat variability coefficient. Thus variability mapping yields information about the antibody-antigen interaction that is useful and complementary to that obtained by alanine scanning mutagenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206766     DOI: 10.1016/s0022-2836(02)00677-0

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

1.  Two surfaces on the histone chaperone Rtt106 mediate histone binding, replication, and silencing.

Authors:  Rachel M Zunder; Andrew J Antczak; James M Berger; Jasper Rine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-23       Impact factor: 11.205

Review 2.  Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

Authors:  J M Boulter; B K Jakobsen
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Probing a protein-protein interaction by in vitro evolution.

Authors:  George Thom; Alexis C Cockroft; Andrew G Buchanan; Cathy Joberty Candotti; E Suzanne Cohen; David Lowne; Phill Monk; Celia P Shorrock-Hart; Lutz Jermutus; Ralph R Minter
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

4.  A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches.

Authors:  Megan L Murtaugh; Sean W Fanning; Tressa M Sharma; Alexandra M Terry; James R Horn
Journal:  Protein Sci       Date:  2011-08-03       Impact factor: 6.725

5.  Generation of recombinant guinea pig antibody fragments to the human GABAC receptor.

Authors:  Adnan Memic; Veronica V Volgina; Hélène A Gussin; David R Pepperberg; Brian K Kay
Journal:  J Immunol Methods       Date:  2011-02-26       Impact factor: 2.303

6.  Comparison of Rosetta flexible-backbone computational protein design methods on binding interactions.

Authors:  Amanda L Loshbaugh; Tanja Kortemme
Journal:  Proteins       Date:  2019-08-10

7.  Assessment of flexible backbone protein design methods for sequence library prediction in the therapeutic antibody Herceptin-HER2 interface.

Authors:  Mariana Babor; Daniel J Mandell; Tanja Kortemme
Journal:  Protein Sci       Date:  2011-05-03       Impact factor: 6.725

8.  Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells.

Authors:  Jayati Jain; Gianluca Veggiani; Mark Howarth
Journal:  Cancer Res       Date:  2013-02-01       Impact factor: 12.701

9.  Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.

Authors:  Petra Kornberger; Arne Skerra
Journal:  MAbs       Date:  2013-12-09       Impact factor: 5.857

10.  Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.

Authors:  Panagiotis Karagiannis; Josef Singer; James Hunt; Samuel K E Gan; Sarah M Rudman; Diana Mechtcheriakova; Regina Knittelfelder; Tracy R Daniels; Philip S Hobson; Andrew J Beavil; James Spicer; Frank O Nestle; Manuel L Penichet; Hannah J Gould; Erika Jensen-Jarolim; Sophia N Karagiannis
Journal:  Cancer Immunol Immunother       Date:  2008-10-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.